Glucocorticoid-prescribing trends in congenital adrenal hyperplasia, 2017 to 2023
Objective: This study investigates the utilisation of modern glucocorticoid medications (Acecort®, Alkindi®, Efmody®, and Plenadren®) for congenital adrenal hyperplasia due to 21-hydroxylase deficiency, examining prescribing patterns, barriers to adoption, and geographical and temporal trends. Metho...
Tallennettuna:
| Päätekijät: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Bioscientifica
2026-03-01
|
| Sarja: | Endocrine Connections |
| Aiheet: | |
| Linkit: | https://ec.bioscientifica.com/view/journals/ec/15/3/EC-25-0565.xml |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|
